284 related articles for article (PubMed ID: 22539224)
1. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Kim W; Ryan CJ
Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
[TBL] [Abstract][Full Text] [Related]
2. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
3. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Mezynski J; Pezaro C; Bianchini D; Zivi A; Sandhu S; Thompson E; Hunt J; Sheridan E; Baikady B; Sarvadikar A; Maier G; Reid AHM; Mulick Cassidy A; Olmos D; Attard G; de Bono J
Ann Oncol; 2012 Nov; 23(11):2943-2947. PubMed ID: 22771826
[TBL] [Abstract][Full Text] [Related]
4. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
5. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Albiges L; Loriot Y; Massard C; Fizazi K
Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
[No Abstract] [Full Text] [Related]
6. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
7. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Pal SK; Lewis B; Sartor O
Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
[TBL] [Abstract][Full Text] [Related]
8. Changing therapeutic paradigms in castrate-resistant prostate cancer.
Zivi A; Massard C; De-Bono J
Clin Genitourin Cancer; 2010 Dec; 8(1):17-22. PubMed ID: 21208851
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
10. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Gupta E; Guthrie T; Tan W
BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
[TBL] [Abstract][Full Text] [Related]
11. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
De Maeseneer DJ; Van Praet C; Lumen N; Rottey S
Urol Oncol; 2015 Jul; 33(7):310-21. PubMed ID: 25708954
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
14. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
15. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor.
Friedlander TW; Ryan CJ
Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
18. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
Grist E; de Bono JS; Attard G
J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
